Bank of America’s $250M Pill Bet Is a Surrender, Not a Strategy
Bank of America’s $250M annual GLP-1 drug spend isn’t healthcare generosity — it’s a calculated workaround. By outsourcing obesity management to pharmaceutical companies, the bank avoids fixing the workplace culture that made employees sick in the first place, while locking itself into a rising drug-price spiral that treats symptoms, not systems.